Mounjaro (Tirzepatide) for Adolescents Age 12 to 17: Off-Label Use, Evidence, and Clinical Considerations

What Is Mounjaro and Why Are Families Asking About It for Teens?

Tirzepatide (Mounjaro) is a once-weekly injectable peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor simultaneously. The FDA approved it in May 2022 for type 2 diabetes in adults, and the same molecule under the brand name Zepbound received approval in November 2023 for adult chronic weight management. [1]

The interest in using it for teenagers has grown rapidly because the adult weight-loss numbers are striking. In SURMOUNT-1 (N=2,539), the 15 mg dose produced a mean body weight reduction of 20.9% at 72 weeks versus 3.1% with placebo (P<0.001). [2] Parents and some clinicians are asking whether those results could translate to a 14-year-old with severe obesity.

Why Adolescent Obesity Demands Effective Treatment

Roughly 19.7% of U.S. Children and adolescents aged 2 to 19 carry a diagnosis of obesity, according to 2017 to 2020 National Health and Nutrition Examination Survey data published by the CDC. [3] Obesity in adolescence tracks strongly into adulthood and is associated with early-onset type 2 diabetes, hypertension, sleep apnea, and non-alcoholic fatty liver disease.

The American Academy of Pediatrics (AAP) 2023 Clinical Practice Guideline on obesity treatment states: "Clinicians should offer adolescents 12 years and older with obesity weight loss pharmacotherapy, according to medication indications, risks, and benefits, as an adjunct to health behavior and lifestyle treatment." [4] The guideline names liraglutide and orlistat; it does not name tirzepatide because no pediatric approval exists yet.

The Gap Between Adult Results and Adolescent Approval

Drug approvals require age-specific trials because puberty alters pharmacokinetics, hormone axes, bone density accrual, and lean mass development. An adult dataset does not satisfy FDA standards for a pediatric indication. That gap is precisely why tirzepatide sits in off-label territory for every patient under 18.

Current FDA Approval Status for Tirzepatide Under Age 18

Tirzepatide has no FDA-approved indication for anyone under 18. The FDA drug label for Mounjaro lists the approved population as adults only. [1] The Zepbound label mirrors that restriction. [5]

What "Off-Label" Means in Practice

Off-label prescribing is legal. Physicians may prescribe any approved drug for any age, dose, or indication they believe is clinically justified, provided they document the rationale and obtain informed consent. The FDA does not regulate the practice of medicine. What off-label status does mean, practically, is that:

• Insurance coverage is often denied, requiring prior authorization or appeal.
• The prescribing physician accepts full medicolegal responsibility.
• No pediatric pharmacokinetic data exists to guide dose selection in a 12-year-old.
• Adverse events in this population are not captured in any systematic post-marketing registry for tirzepatide.

Comparison to Approved Pediatric Weight-Loss Agents

Two GLP-1-based agents carry FDA approval for weight management in adolescents aged 12 and older. Liraglutide 3 mg (Saxenda) was approved for this group in December 2020, based on a randomized trial (N=251) that showed a 5.0 percentage-point greater reduction in BMI z-score versus placebo. [6] Semaglutide 2.4 mg (Wegovy) received approval for ages 12 and older in December 2022, based on the STEP TEENS trial (N=201), in which adolescents achieved a 16.1% mean BMI reduction versus a 0.6% increase in the placebo arm. [7]

Tirzepatide offers dual-receptor activation that appears to produce greater weight reduction in adults than semaglutide alone, but no equivalent pediatric randomized controlled trial exists for tirzepatide as of this writing.

The SURPASS-PEDS Trial: What Is Currently Known

The most directly relevant data source is SURPASS-PEDS (ClinicalTrials.gov identifier NCT05596474), a phase 3, randomized, double-blind, placebo-controlled trial designed specifically to evaluate tirzepatide in pediatric participants. [8]

Trial Design

SURPASS-PEDS enrolls participants aged 10 to 17 with a diagnosis of obesity (BMI at or above the 95th percentile for age and sex) or overweight (BMI between the 85th and 94th percentile) plus at least one weight-related comorbidity. The trial tests tirzepatide 5 mg, 10 mg, and 15 mg versus placebo, with a primary endpoint of percentage change in body weight at 52 weeks.

Expected Timeline and Interim Limitations

The trial was still enrolling as of early 2025. Full results are expected no earlier than late 2025 or 2026, pending enrollment completion and data lock. Until those results are published, clinicians considering off-label use for a teenager have no tirzepatide-specific pediatric efficacy or safety signal to draw on.

Why Adult Data Cannot Be Extrapolated Directly

Adolescents experience rapid changes in body composition, insulin sensitivity, sex hormone levels, and bone mineral density accrual. GLP-1 and GIP receptors are expressed in bone tissue, and at least one analysis of adult liraglutide trials suggested a small, non-significant trend toward reduced bone mineral density with prolonged use. [9] The clinical significance in a teenager whose peak bone mass has not yet been reached is unknown and cannot be dismissed.

Safety Profile of Tirzepatide Relevant to Adolescents

Black-Box Warning: Thyroid C-Cell Tumors

Every tirzepatide label carries a boxed warning for thyroid C-cell tumors based on rodent carcinogenicity studies. The FDA states: "The human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been established." [1] Pediatric endocrinologists frequently flag this warning because thyroid function and growth hormone axes are tightly linked during adolescence. Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Gastrointestinal Adverse Effects

In SURMOUNT-1, nausea was reported in 31% of tirzepatide 15 mg recipients versus 11% of placebo recipients. [2] Vomiting occurred in 19% versus 5%, and diarrhea in 23% versus 15%. Adolescents in active growth phases have different caloric and micronutrient requirements than adults, and sustained nausea or vomiting during a growth spurt could impair adequate nutrition.

Pancreatitis and Gallbladder Disease

The class carries a risk of acute pancreatitis and cholelithiasis. The SURMOUNT-1 trial reported cholelithiasis in 1.0% of the highest-dose group versus 0.4% placebo. [2] Pediatric gallstone disease is rare but does occur, particularly in adolescents with obesity, and the additive risk from tirzepatide in a teenager has not been characterized.

Injection Site Reactions and Needle Acceptability

Approximately 7% of adults in SURMOUNT-1 reported injection site reactions. In adolescents, needle phobia and injection-site compliance are real clinical barriers. Pediatric GLP-1 trials such as STEP TEENS showed that once-weekly self-injection was feasible with structured training, but individual variation among 12 to 17-year-olds is wide. [7]

A Clinical Decision Framework for Prescribers Considering Off-Label Tirzepatide in Ages 12 to 17

Prescribers who receive requests for tirzepatide in this age group should work through the following questions before writing any prescription.

Step 1: Has the Patient Tried Approved First-Line Options?

The AAP 2023 guideline recommends intensive health behavior and lifestyle treatment as the foundation, with pharmacotherapy added when behavioral treatment alone is insufficient. [4] Approved agents, specifically semaglutide 2.4 mg (Wegovy) for ages 12 and older, should be trialed first given the pediatric randomized controlled trial evidence behind them. Off-label tirzepatide is not a first-line choice.

Step 2: Is There a Compelling Clinical Reason to Prefer Tirzepatide?

In adults, head-to-head data from the SURMOUNT-5 trial (N=751) showed tirzepatide 10 mg or 15 mg produced a 20.2% mean body weight reduction versus 13.7% with semaglutide 2.4 mg at 72 weeks (P<0.001). [10] A prescriber might argue that a teen with severe obesity, significant comorbidities, and inadequate response to approved agents has a compelling case. That argument is clinically defensible but must be documented.

Step 3: Are Contraindications Absent?

Contraindications include personal or family history of medullary thyroid carcinoma, MEN2, prior serious hypersensitivity to tirzepatide, and pregnancy or intent to become pregnant. Age alone does not create an absolute contraindication, but the absence of pediatric pharmacokinetic data means no dose is formally validated.

Step 4: Is Informed Consent Documented?

Informed consent for off-label use in a minor requires that both the adolescent (assent) and the parent or legal guardian (consent) understand the following:

• No FDA approval exists for this age group.
• Long-term effects on growth, bone density, and pubertal development are unknown.
• The trial data cited are from adults and may not predict outcomes in adolescents.
• The prescribing physician is working outside labeling and accepts associated responsibility.

Step 5: Is a Pediatric Specialist Involved?

A prescribing primary care physician or internist should strongly consider co-management with a board-certified pediatric endocrinologist when initiating off-label tirzepatide in a minor. The Pediatric Endocrine Society (PES) and the AACE/ACE obesity guidelines both recommend multidisciplinary team involvement for pharmacotherapy in pediatric patients. [11]

Dosing Considerations When Off-Label Use Proceeds

No pediatric dosing regimen exists in the tirzepatide label. Adult dosing starts at 2.5 mg once weekly for 4 weeks, then increases in 2.5 mg steps every 4 weeks to a maintenance dose between 5 mg and 15 mg as tolerated. [1]

Weight-Based Dosing in Adolescents

No weight-adjusted dosing algorithm has been validated for tirzepatide in adolescents. Body weight in a 12-year-old may range from 40 kg to over 100 kg depending on height, sex, and obesity severity. Some pediatric endocrinologists apply a conservative approach modeled on the semaglutide STEP TEENS protocol, which used the standard adult dose without weight-based adjustment, but achieved it via a slower titration schedule to reduce GI side effects. [7] Whether that approach is appropriate for tirzepatide is speculative.

Monitoring Parameters

Any prescriber proceeding with off-label tirzepatide in this age group should monitor:

• Body weight and BMI percentile at every visit.
• Height velocity (to detect any growth suppression signal early).
• Fasting glucose and HbA1c at baseline and every 3 months.
• Thyroid function (TSH, free T4) at baseline and at 3 and 6 months.
• Caloric intake and nutritional adequacy, given GI side effects.
• Mental health screen, because rapid weight change in adolescents can interact with body image concerns and eating disorder risk.

The STEP TEENS trial screened participants for eating disorders at baseline and excluded those with active disorders. [7] That same screening standard should be applied before any GLP-1 or GIP/GLP-1 agent is started in an adolescent.

Regulatory Pathway and What to Expect from SURPASS-PEDS Results

If SURPASS-PEDS shows adequate efficacy and an acceptable safety profile, Eli Lilly could submit a supplemental new drug application (sNDA) or biologics license application supplement to FDA requesting a pediatric indication. That process typically takes 12 to 18 months after submission under the Pediatric Research Equity Act (PREA), which actually requires sponsors to study drugs in pediatric populations when the adult indication involves a disease that also occurs in children. [12]

The FDA's Oncologic Drugs Advisory Committee has previously scrutinized the thyroid C-cell tumor signal for GLP-1 agents in depth. Any pediatric application for tirzepatide will face particularly detailed thyroid safety review given the growth and hormonal context of the 12 to 17 age bracket.

Practical Guidance for Families Asking About Mounjaro for a Teenager

Families who ask a pediatrician or primary care physician about tirzepatide for their adolescent deserve a direct and honest answer.

• No approval exists. A provider prescribing it accepts the full medicolegal and clinical risk.
• Two approved options exist. Semaglutide 2.4 mg (Wegovy) has a 201-patient randomized controlled trial in adolescents and an FDA label that specifically covers ages 12 and older. [7] That evidence base is stronger than anything currently available for tirzepatide in this age group.
• The adult data are encouraging but not pediatric data. A 16-year-old is not a small adult. Hormonal, metabolic, and skeletal physiology differs in ways that matter for a weekly injectable that affects GIP and GLP-1 axes.
• Clinical trials represent the safest path. Families interested in tirzepatide for their teenager should ask their physician about enrolling in SURPASS-PEDS or other active pediatric trials, where monitoring is systematic and data contribute to the evidence base.
• Lifestyle treatment remains the foundation. The AAP 2023 guideline is explicit: "Clinicians should offer intensive health behavior and lifestyle treatment," with a minimum of 26 contact hours in the first year. [4] No injectable replaces that foundation.

The average American adolescent with obesity sees meaningful clinical benefit from even a 5 to 10% reduction in body weight, which is achievable with approved options. Chasing a larger number with an unapproved agent in a 13-year-old is not automatically the right clinical trade-off.